Aardvark Therapeutics (AARD) News Today $4.51 +0.22 (+5.13%) Closing price 05/21/2026 04:00 PM EasternExtended Trading$4.44 -0.07 (-1.64%) As of 05/21/2026 06:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AARD Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 Time Period INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARDMay 21 at 6:40 PM | prnewswire.comAardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSSMay 21 at 9:00 AM | prnewswire.comAardvark Therapeutics, Inc. (NASDAQ:AARD) Receives Consensus Rating of "Hold" from BrokeragesMay 21 at 2:15 AM | americanbankingnews.comAardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens BermanMay 19 at 12:30 PM | prnewswire.comAardvark Therapeutics: Regulatory Uncertainty Clouds ARD-101 Path ForwardMay 18, 2026 | seekingalpha.comFDA hold puts Aardvark Prader-Willi drug in limboMay 15, 2026 | finance.yahoo.comAARD stock crashes 34% – here’s why this analyst finds it ‘hard to lean into’ Aardvark at this stageMay 15, 2026 | msn.comAardvark Therapeutics Shares Plunge After FDA Hold on ARD-101 New Drug ApplicationMay 15, 2026 | marketwatch.comAardvark Therapeutics Says FDA Placed Hold on ARD-101 TrialsMay 14, 2026 | marketwatch.comFDA Clinical Hold Halts Aardvark’s ARD-101 Late-Stage ProgramMay 14, 2026 | tipranks.comFDA places full clinical hold on Aardvark's drug for extreme hunger in Prader-Willi syndromeMay 14, 2026 | reuters.comAardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical HoldMay 14, 2026 | globenewswire.comAardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens BermanMay 14, 2026 | globenewswire.comAardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens BermanMay 7, 2026 | prnewswire.comAardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdatesMay 7, 2026 | globenewswire.comAardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens BermanApril 28, 2026 | globenewswire.comAardvark Therapeutics, Inc. (NASDAQ:AARD) Given Average Rating of "Moderate Buy" by BrokeragesApril 26, 2026 | marketbeat.comAardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens BermanApril 22, 2026 | prnewswire.comAardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens BermanApril 14, 2026 | globenewswire.comAardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens BermanApril 10, 2026 | prnewswire.comAardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens BermanApril 9, 2026 | globenewswire.comAardvark Therapeutics (AARD) price target decreased by 43.62% to 18.77March 27, 2026 | msn.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARDMarch 26, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARDMarch 24, 2026 | globenewswire.comAardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdatesMarch 23, 2026 | globenewswire.comAardvark’s ARD-101 Prader-Willi Study Suspended: What Investors Should Watch NextMarch 19, 2026 | tipranks.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARDMarch 19, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARDMarch 17, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARDMarch 12, 2026 | prnewswire.comAardvark Therapeutics, Inc. Investigated by the Portnoy Law FirmMarch 11, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARDMarch 10, 2026 | globenewswire.comA Look At Aardvark Therapeutics (AARD) Valuation After The Voluntary Pause Of Its Phase 3 HERO TrialMarch 5, 2026 | finance.yahoo.comAardvark Therapeutics (AARD) Is Down 61.4% After Pausing Phase 3 HERO Trial Over Cardiac Safety QuestionsMarch 4, 2026 | finance.yahoo.comWhat's Going On With Aardvark Therapeutics Stock On Wednesday?March 4, 2026 | benzinga.comAARD Investors Have Opportunity to Join Aardvark Therapeutics, Inc. Fraud Investigation with the Schall Law FirmMarch 4, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARDMarch 3, 2026 | globenewswire.comAardvark Therapeutics stock plunges after trial pauseMarch 2, 2026 | in.investing.comWhy Is Aardvark Therapeutics Stock Sinking Monday?March 2, 2026 | benzinga.comAARD Investors Have Opportunity to Join Aardvark Therapeutics, Inc. Fraud Investigation With the Schall Law FirmFebruary 28, 2026 | businesswire.comAardvark Therapeutics, Inc.: Aardvark Therapeutics Announces Voluntary Pause of Phase 3 HERO Trial in Prader-Willi SyndromeFebruary 28, 2026 | finanznachrichten.deStocks to Watch: Aardvark Therapeutics, Blue Moon MetalsFebruary 27, 2026 | marketwatch.comAardvark pauses late-stage trial testing rare disease treatmentFebruary 27, 2026 | yahoo.comAardvark Therapeutics Pauses Trial After Finding Safety IssueFebruary 27, 2026 | marketwatch.comAardvark Pauses ARD-101 Phase 3 HERO Trial EnrollmentFebruary 27, 2026 | tipranks.comAardvark Therapeutics, Inc. Pauses Phase 3 HERO Trial for ARD-101 Due to Safety ObservationsFebruary 27, 2026 | quiverquant.comQAardvark Therapeutics Announces Voluntary Pause of Phase 3 HERO Trial in Prader-Willi SyndromeFebruary 27, 2026 | globenewswire.comAardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 13, 2026 | globenewswire.comAardvark Therapeutics Announces Establishment of New U.S. Subsidiary to Support Development of Its Dermatology Pipeline; Bryan Jones Named Chief Executive OfficerFebruary 12, 2026 | globenewswire.comAardvark Therapeutics Announces Leadership AppointmentsFebruary 12, 2026 | globenewswire.comAardvark gains IRB approval for ARD-101 trial to treat Prader-Willi syndromeFebruary 11, 2026 | msn.com Get Aardvark Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AARD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AARD Media Mentions By Week AARD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AARD News Sentiment▼-0.060.40▲Average Medical News Sentiment AARD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AARD Articles This Week▼104▲AARD Articles Average Week Get the Latest News and Ratings for AARD and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Aardvark Therapeutics and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies PRME News TECX News AVTX News ANL News IMMX News CTNM News ALLO News PROK News FDMT News DNA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AARD) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersSystem failure: The strongest leverage for gold…$9 trillion in U.S. debt must be refinanced in 2026 - at current rates - while the largest foreign buyers of T...Golden Portfolio | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredI had never heard of this 1888 accountAn investment account dating back to 1888 has quietly delivered average annual returns of 29% over the last 25...The Oxford Club | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredSpaceX controls two-thirds of all satellites - and it is about to go publicSpaceX is targeting an IPO on June 11th, with trading set to begin June 12th and the roadshow kicking off June...NXT Wave Research | SponsoredHow to Profit from Elon’s AI lab before it goes publicElon Musk's AI lab has partnered with the Department of Defense, Oracle, and Palantir - and he just filed conf...InvestorPlace | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aardvark Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aardvark Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
